VCYT | Veracyte, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	40.30 - 41.29
52 Week Range	18.61 - 46.00
Beta	2.17
Implied Volatility	77.43%
IV Rank	37.68%
Day's Volume	183,504
Average Volume	795,861
Shares Outstanding	77,499,600
Market Cap	3,191,433,528
Sector	Healthcare
Industry	Biotechnology
IPO Date	2013-10-30

Valuation
Profitability
Growth
Health
P/E Ratio	-316.77
Forward P/E Ratio	-24.38
EPS	-0.13
1YR Price Target	30.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	815
Country	USA
Website	VCYT

Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. The company derives its revenues from the Sale of Afirma analysis product.

VCYT's peers: MCRB, MDWD, TXG, CRNX, VRDN, CYTK, GPCR, ICVX, KURA, PTGX, MRUS, REPL, CERE, ENTA, SNDX, VTYX, QURE, RCKT, RYTM, SLDB, MGTX, IDYA, ANAB, KROS, FIXX, VYNE

*Chart delayed

Analyzing fundamentals for VCYT we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is on medium level and Health is passable. For more detailed analysis please see VCYT Fundamentals page.

Watching at VCYT technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on VCYT Technicals page.